Contracts
Framework
NHS National Framework for Lenvatinib
NHS England is establishing a national framework agreement for Lenvatinib (a cancer drug) across three regional lots. Suppliers will be appointed to provide the medicine to NHS services in their respective regions.
- Closes30 October 2026, 13:00
- Published30 September 2026
- Value£36m
- Per lot£12m across 3 lots
- BuyerNHS England
- WhereCentral and South West (Lot 1), North West and London/North (Lot 2), London, South East and North East (Lot 3)
- CategoryHealth & medical
- RegionUK-wide
You'll want to look if you are a licensed pharmaceutical supplier with capacity to distribute Lenvatinib to NHS services in Central and South West, North West and London/North, or London, South East and North East England.
Might not suit a small firm
- the contract itself is a large one
- it needs coverage across the whole UK
Possible incumbent
Mercury Pharmaceuticals Limited won recent NHS pharmaceutical frameworks including Golimumab and Omalizumab in 2025. Inferred from prior awards to this buyer, not confirmed.